- Home
- NLSP
as 06-27-2025 3:32pm EST
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
| Founded: | 2015 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 12.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 325.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $16.00 | Next Earning Date: | 07-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NLS Pharmaceutics Ltd. News
NLSP Breaking Stock News: Dive into NLSP Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
NLS Pharmaceutics CEO Issues Letter to Shareholders
PR Newswire
a month ago
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
MT Newswires
2 months ago
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder
PR Newswire
2 months ago
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
ACCESS Newswire
3 months ago
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
PR Newswire
4 months ago
NLS Pharmaceutics CEO Issues Letter to Shareholders
PR Newswire
4 months ago
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
PR Newswire
4 months ago
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Compare NLSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NLSP NLS Pharmaceutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.